Apoptotic effect of linifanib on human ovarian cancer OVCAR3 cell line

Han Ki Lee, Jongsung Lee, Myeong Jin Nam, Hyun Gi Koh, Kyungmoon Park, Kyu Yun Jang , See-Hyoung Park

Abstract


Background and purpose: Linifanib is a multi-targeted receptor tyrosine kinase inhibitor. Although it is widely recognized for its efficacy in inhibiting receptor tyrosine kinases, its anticancer effects in ovarian cancer have not been extensively studied. In this study, we investigated the anticancer effects of linifanib on human ovarian cancer OVCAR3 cells.

Experimental approach: To evaluate cell proliferation capacity, we performed MTT assays, cell counting, morphological analysis, and colony formation assays. Flow cytometry was used to assess the induction of apoptotic cells by linifanib, and DNA fragmentation was evaluated using TUNEL assays. Western blotting was performed to determine the protein expression levels related to apoptosis.

Findings/Results: Our results demonstrated that linifanib significantly inhibited the proliferation of OVCAR3 cells and induced apoptosis. Notably, treatment with linifanib led to the inhibition of phosphorylated Akt at Ser473, accompanied by the activation of FOXO3.

Conclusion and implications: Taken together, these findings indicate that linifanib suppresses the proliferation of human ovarian cancer OVCAR3 cells, highlighting its potential as a therapeutic candidate for ovarian cancer treatment.

 

 


Keywords


Apoptosis; FOXO3; Linifanib; Ovarian cancer; OVCAR3.

Full Text:

PDF

References


Pokhriyal R, Hariprasad R, Kumar L, Hariprasad G. Chemotherapy resistance in advanced ovarian cancer patients. Biomark Cancer. 2019;11:1-19.DOI: 10.1177/1179299X19860815.

Huang J, Chan WC, Ngai CH, Lok V, Zhang L, Lucero-Prisno DE, et al. Worldwide burden, risk factors, and temporal trends of ovarian cancer: a global study. Cancers (Basel). 2022;14(9):2230,1-12.DOI: 10.3390/cancers14092230.

Duska LR, Tew WP, Moore KN. Epithelial ovarian cancer in older women: defining the best management approach. Am Soc Clin Oncol Educ Book. 2015:e311-e321.DOI:10.14694/EdBook_AM.2015.35.e311.

Rooth C. Ovarian cancer: risk factors, treatment and management. Br J Nurs. 2013;22(Sup17):S23-S30.DOI: 10.12968/bjon.2013.22.Sup17.S23.

Ramus SJ, Gayther SA. The contribution of BRCA1 and BRCA2 to ovarian cancer. Mol Oncol. 2009;3(2):138-150.DOI: 10.1016/j.molonc.2009.02.001.

Yang C, Xia BR, Zhang ZC, Zhang YJ, Lou G, Jin WL. Immunotherapy for ovarian cancer: adjuvant, combination, and neoadjuvant. Front Immunol. 2020;11:1-18.DOI: 10.3389/fimmu.2020.577869.

Macchia G, Lazzari R, Colombo N, Laliscia C, Capelli G, D’Agostino GR, et al. A large, multicenter, retrospective study on efficacy and safety of stereotactic body radiotherapy in oligometastatic ovarian cancer (MITO RT1 Study):a collaboration of MITO, AIRO GYN, and MaNGO. Oncologist. 2020;25(2):e311-e320.DOI: 10.1634/theoncologist.2019-0309.

López-Reig R, López-Guerrero JA. The hallmarks of ovarian cancer:proliferation and cell growth. Eur J Cancer Suppl. 2020;15:27-37.DOI: 10.1016/j.ejcsup.2019.12.001.

Glaviano A, Singh SK, Lee EHC, Okina E, Lam HY, Carbone D, et al. Cell cycle dysregulation in cancer. Pharmacol Rev. 2025;77(2):100030.DOI: 10.1016/j.pharmr.2024.100030.

Bai J, Li Y, Zhang G. Cell cycle regulation and anticancer drug discovery. Cancer Biol Med. 2017;14(4):348-362.DOI: 10.20892/j.issn.2095-3941.2017.0033.

Zoń A, Bednarek I. Cisplatin in ovarian cancer treatment: known limitations in therapy force new solutions. Int J Mol Sci. 2023;24(8):1-20.DOI: 10.3390/ijms24087585.

Jiang C, Shen C, Ni M, Huang L, Hu H, Dai Q, et al. Molecular mechanisms of cisplatin resistance in ovarian cancer. Genes Dis. 2023;11(6):101063,1-16.DOI: 10.1016/j.gendis.2023.06.032.

Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, et al. Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(2):191-226.DOI: 10.6004/jnccn.2021.0007.

Nag S, Aggarwal S, Rauthan A, Warrier N. Maintenance therapy for newly diagnosed epithelial ovarian cancer – a review. J Ovarian Res. 2022;15(1):88,1-18.DOI: 10.1186/s13048-022-01020-1.

Wang L, Wang X, Zhu X, Zhong L, Jiang Q, Wang Y, et al. Drug resistance in ovarian cancer: from mechanism to clinical trial. Mol Cancer. 2024;23(1):66,1-26.DOI: 10.1186/s12943-024-01967-3.

Konstantinopoulos PA, Matulonis UA. Clinical and translational advances in ovarian cancer therapy. Nat Cancer. 2023;4(9):1239-1257.DOI: 10.1038/s43018-023-00617-9.

Marlow M, Al-Ameedee M, Smith T, Wheeler S, Stocks MJ. Linifanib – a multi-targeted receptor tyrosine kinase inhibitor and a low molecular weight gelator. Chem Commun (Camb). 2015;51(29): 6384-6387.DOI: 10.1039/c5cc00454c.

Hernandez-Davies JE, Zape JP, Landaw EM, Tan X, Presnell A, Griffith D, et al. The multitargeted receptor tyrosine kinase inhibitor linifanib (ABT-869) induces apoptosis through an Akt and GSK3β-dependent pathway. Mol Cancer Ther. 2011;10(6):949-959.DOI: 10.1158/1535-7163.MCT-10-0904.

Chen J, Guo J, Chen Z, Wang J, Liu M, Pang X. Linifanib potentiates the efficacy of chemotherapeutic agents through the suppression of RTK-mediated AKT/mTOR signaling pathways in gastric cancer. Sci Rep. 2016;6:29382,1-11.DOI: 10.1038/srep29382.

Aversa C, Leone F, Zucchini G, Serini G, Geuna E, Milani A, et al. Linifanib: current status and future potential in cancer therapy. Expert Rev Anticancer Ther. 2015;15(6):677-687.DOI: 10.1586/14737140.2015.1042369.

Wang ES, Yee K, Koh LP, Hogge D, Enschede S, Carlson DM, et al. Phase 1 trial of linifanib in patients with refractory or relapsed acute myeloid leukemia. Leuk Lymphoma. 2012;53(8):1543-1551.DOI: 10.3109/10428194.2012.660631.

Luo Y, Jiang F, Cole TB, Hradil VP, Reuter D, Chakravartty A, et al. A novel multi-targeted tyrosine kinase inhibitor, linifanib produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model. Cancer Chemother Pharmacol. 2012;69(4):911-921.DOI: 10.1007/s00280-011-1740-7.

Elgawish MS, Abdeldayem E. Vascular endothelial growth factor receptors (VEGFR/PDGFR) inhibitors. In: Asati V, Vaidya A. Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy. Academic Press; 2024. pp. 443-475.DOI: 10.1016/C2021-0-01846-0.

Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484-2496.DOI: 10.1056/NEJMoa1103799.

Yang JH, Petty CA, Dixon-McDougall T, Lopez MV, Tyshkovskiy A, Maybury-Lewis S, et al. Chemically induced reprogramming to reverse cellular aging. Aging (Albany NY). 2023;15(13):5966-5989.DOI: 10.18632/aging.204896.

Albert DH, Tapang P, Magoc TJ, Pease LJ, Reuter DR, Wei RQ, et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther. 2006;5(4):995-1006.DOI: 10.1158/1535-7163.MCT-05-0410.

Hsu HW, de Necochea-Campion R, Williams V, Duerksen-Hughes PJ, Simental AA, Ferris RL, et al. Linifanib enhances cytotoxicity with PARP inhibitor veliparib in head and neck carcinoma cells. Oral Oncol. 2014;50(7):662-669.DOI: 10.1016/j.oraloncology.2014.03.006.

Banchi M, Orlandi P, Gentile D, Alì G, Fini E, Fontanini G, et al. Synergistic activity of linifanib and irinotecan increases survival in mice bearing human anaplastic thyroid cancer. Am J Cancer Res. 2020;10(7):2120-2127.PMID: 32775005.

Mudd SR, Voorbach MJ, Reuter DR, Tapang P, Hickson JA, Refici-Buhr M, et al. FDG-PET as a pharmacodynamic biomarker for early assessment of linifanib treatment response in NSCLC xenografts. Cancer Chemother Pharmacol. 2012;69(6): 1669-1672.DOI: 10.1007/s00280-012-1840-z.

Lee CM, Lee J, Kang MA, Kim HT, Lee J, Park K, et al. Linifanib induces apoptosis in human ovarian cancer cells via activation of FOXO3 and ROS. Arab J Chem. 2022;15(12):104321,1-15.DOI: 10.1016/j.arabjc.2022.104321.

Tan EH, Goss GD, Salgia R, Besse B, Gandara DR, Hanna NH, et al. Phase 2 trial of linifanib in patients with advanced NSCLC. J Thorac Oncol. 2011;6(8):1418-1425.DOI: 10.1097/JTO.0b013e318220c93e.

Tannir NM, Wong YN, Kollmannsberger CK, Ernstoff MS, Perry DJ, Appleman LJ, et al. Phase 2 trial of linifanib in patients with advanced renal cell cancer after sunitinib failure. Eur J Cancer. 2011;47(18):2706-2714.DOI: 10.1016/j.ejca.2011.09.002.

Bradbury A, O’Donnell R, Drew Y, Curtin NJ, Sharma Saha S. Characterisation of ovarian cancer cell line NIH-OVCAR3 and implications of biomarkers for therapy. Cancers (Basel). 2020;12(7):1939,1-17.DOI: 10.3390/cancers12071939.

Al-Alem LF, Baker AT, Pandya UM, Eisenhauer EL, Rueda BR. Understanding and targeting apoptotic pathways in ovarian cancer. Cancers (Basel). 2019;11(11):1631,1-27.DOI: 10.3390/cancers11111631.

Simmons AD, Nguyen M, Pintus E. Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report.BMC Cancer. 2020;20:215,1-6. DOI: 10.1186/s12885-020-6657-2.

Dejean AS, Beisner DR, Ch’en IL, Kerdiles YM, Babour A, Arden KC, et al. Foxo3 controls magnitude of T cell responses via dendritic cells. Nat Immunol. 2009;10(5):504-513.DOI: 10.1038/ni.1729.

Webb AE, Brunet A. FOXO transcription factors:key regulators of cellular quality control. Trends Biochem Sci. 2014;39(4):159-167.DOI: 10.1016/j.tibs.2014.02.003.

Jiang L, Cao XC, Cao JG, Liu F, Quan MF, Sheng XF, et al. Casticin induces ovarian cancer apoptosis by repressing FoxM1 via FOXO3a. Oncol Lett. 2013;5(5):1605-1610.DOI: 10.3892/ol.2013.1258.

Park SH, Lee JH, Berek JS, Hu MC. Auranofin shows anticancer activity in ovarian cancer via FOXO3 activation. Int J Oncol. 2014;45(4): 1691-1698.DOI: 10.3892/ijo.2014.2579.

Zhu D, Yuan D, Guo R, Zhang L, Guo T, Zhao Y, et al. Overexpression of miR-148a inhibits viability and invasion of OVCAR3 cells by targeting FOXO3. Oncol Lett. 2019;18(1):402-410.DOI: 10.3892/ol.2019.10321.

Pan H, Wang Z, Jiang L, Sui X, You L, Shou J, et al. Autophagy inhibition sensitizes hepatocellular carcinoma to the multikinase inhibitor linifanib. Sci Rep. 2014;4(1): 6683,1-11.DOI: 10.1038/srep06683.


Refbacks

  • There are currently no refbacks.


Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.